A Translational Model‐Based Meta‐Analysis to Predict Tremor Incidence Associated with Serotonin Reuptake Transporter Inhibition
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3696 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Sheetal K Panday und 7 weiteren Autor:innen. Beteiligte Einrichtung: Applied BioMath, LLC, Concord, Massachusetts, USA. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Tremor, Serotonin Plasma Membrane Transport Proteins, Models, Biological. Die Arbeit nennt 27 Literaturangaben. Gefördert von: EMD Serono.
Abstract (Originalsprache)
The serotonin reuptake transporter (SERT) is responsible for the removal and recycling of the neurotransmitter serotonin from neuronal synapses and is an important pharmacological target for treating a variety of CNS disorders. However, excessive levels of extrasynaptic serotonin resulting from SERT inhibition can lead to serotonin toxicity, which manifests as a spectrum of adverse events (AEs) termed “serotonin syndrome” (SS), ranging in severity from mild to life‐threatening. We hypothesized that, by performing a model‐based meta‐analysis (MBMA) of the data in the literature, the dose at which tremors (a characteristic manifestation of SS) occur could be predicted based on the pharmacokinetic properties and SERT inhibitory potency of a given drug. To investigate the relationship between tremors and the predicted relative strength of SERT inhibition, a literature survey was performed to collate observed tremor data, pharmacokinetic parameters, and SERT potency data for known SERT inhibitors. Using these data for 20 SERT inhibitors, an E max model relationship between tremor incidence and the ratio between brain unbound exposure and SERT IC50 was observed. The identified relationship provides a valuable tool to predict the likelihood of tremor incidence for investigational drugs with SERT inhibitory activity and to inform safety assessment and dose selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Applied BioMath, LLC, Concord, Massachusetts, USA.
- Differentia Bio, Pleasanton, California, USA.
- Merck KGaA, Darmstadt, Germany.
- EMD Serono, Inc. (Billerica, MA. USA, a business of Merck KGaA), Darmstadt, Germany.
ORCID-Profile: Sheetal K Panday, Benjamin J Lang, Georgi I Kapitanov, Kalyanasundaram Subramanian, Lena Klopp-Schulze, Karthik Venkatakrishnan, Anup Zutshi, Abed E Alnaif
Förderung
- EMD Serono
Zitieren
APA
Panday, S. K., Lang, B. J., Kapitanov, G. I., Subramanian, K., Klopp-Schulze, L., Venkatakrishnan, K., Zutshi, A., & Alnaif, A. E. (2025). A Translational Model‐Based Meta‐Analysis to Predict Tremor Incidence Associated with Serotonin Reuptake Transporter Inhibition. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3696
Vancouver
Panday SK, Lang BJ, Kapitanov GI, Subramanian K, Klopp-Schulze L, Venkatakrishnan K, et al. A Translational Model‐Based Meta‐Analysis to Predict Tremor Incidence Associated with Serotonin Reuptake Transporter Inhibition. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3696
BibTeX
@article{Panday2025,
author = {Panday, Sheetal K and Lang, Benjamin J and Kapitanov, Georgi I and Subramanian, Kalyanasundaram and Klopp-Schulze, Lena and Venkatakrishnan, Karthik and Zutshi, Anup and Alnaif, Abed E},
title = {A Translational Model‐Based Meta‐Analysis to Predict Tremor Incidence Associated with Serotonin Reuptake Transporter Inhibition},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3696}
}
EUVIMED